|
|
PPMS, 1 year of disease progression plus 2 of 3 of following: 1) Evidence for DIS in brain based on >= 1 T2 lesions in MS-characteristic regions, 2) Evidence for DIS in spinal cord, 3) Positive CSF
|
PPMS, 1 year of disease progression plus 2 of 3 of following: 1) Evidence for DIS in brain based on >= 1 T2 lesions in MS-characteristic regions, 2) Evidence for DIS in spinal cord, 3) Positive CSF
|
Primary Progressive Multiple Sclerosis, 1 year of disease progression (retrospectively or prospectively determined) plus 2 of 3 of the following: (1) Evidence for DIS in the brain based on >= 1 T2 lesions in the MS-characteristic (periventricular, juxtacortical, or infratentorial) regions, (2) Evidence for DIS in the spinal cord based on >= 2 T2 lesions in the cord, (3) Positive CSF (isoelectric focusing evidence of oligoclonal bands and/or elevated IgG index)
|
|
|
PRMS, Progressive disease from onset, with clear acute relapses, with or without full recovery, periods between relapses characterized by continuing progression
|
PRMS, Progressive disease from onset, with clear acute relapses, with or without full recovery, periods between relapses characterized by continuing progression
|
Progressive Relapsing Multiple Sclerosis, Progressive disease from onset, with clear acute relapses, with or without full recovery, periods between relapses characterized by continuing progression
|
|
|
RRMS, 1 attack, objective clinical evidence of 1 lesion (clinically isolated syndrome)
|
RRMS, 1 attack, objective clinical evidence of 1 lesion (clinically isolated syndrome)
|
Relapsing Remitting Multiple Sclerosis, 1 attack, objective clinical evidence of 1 lesion (clinically isolated syndrome) [Dissemination in space and time, demonstrated by: >= 1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord)| and For DIT: Simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time, or A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan]
|
|
|
RRMS, 1 attack, objective clinical evidence of >= 2 lesions
|
RRMS, 1 attack, objective clinical evidence of >= 2 lesions
|
Relapsing Remitting Multiple Sclerosis, 1 attack, objective clinical evidence of >= 2 lesions [Dissemination in time, demonstrated by: Simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time, or A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan]
|
|
|
RRMS, >= 2 attacks, objective clinical evidence of 1 lesion
|
RRMS, >= 2 attacks, objective clinical evidence of 1 lesion
|
Relapsing Remitting Multiple Sclerosis, >= 2 attacks, objective clinical evidence of 1 lesion [Dissemination in space demonstrated by: >= 1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord)]
|
|
|
RRMS, >= 2 attacks, objective clinical evidence of >= 2 lesions or objective clinical evidence of 1 lesion with reasonable historical evidence of a prior attack
|
RRMS, >= 2 attacks, objective clinical evidence of >= 2 lesions or objective clinical evidence of 1 lesion with reasonable historical evidence of a prior attack
|
Relapsing Remitting Multiple Sclerosis, >= 2 attacks, objective clinical evidence of >= 2 lesions or objective clinical evidence of 1 lesion with reasonable historical evidence of a prior attack
|
|
|
SPMS, Initial RR disease course followed by progression with or without occasional relapses, minor remissions, and plateaus
|
SPMS, Initial RR disease course followed by progression with or without occasional relapses, minor remissions, and plateaus
|
Secondary Progressive Multiple Sclerosis, Initial Relapsing Remitting disease course followed by progression with or without occasional relapses, minor remissions, and plateaus
|